Aspen files audited 2026 accounts: what it means for Aspen stock

Published on 10/13/2026 at 03:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fiscal 2026 free cash flow reached ZAR 3.8 billion. Aspen stock has an AGM on December 3, 2026 after audited accounts.

Key points in brief

Aspen made its audited fiscal 2026 financial statements available on October 2, 2026.
The company will hold its annual general meeting on December 3, 2026.
Fiscal 2026 free cash flow reached ZAR 3.8 billion and APAC divestment proceeds totaled ZAR 28.0 billion.
Aspen targets normalized EBITDA of at least ZAR 9.0 billion in fiscal 2027.

Aspen, ZAE000066692, Illustration mit AI erstellt.

Aspen Pharmacare Holdings (ZAE000066692) made its audited annual financial statements for fiscal 2026 available on October 2, 2026, while the company set its annual general meeting for December 3, 2026. Sharenet reported that the audited statements contained no modifications to the reviewed results published on September 2, 2026.

What the AGM means for valuation

The December 3 meeting gives shareholders a formal checkpoint after a year of portfolio restructuring. The record date for participation is November 27, 2026, while November 24, 2026 is the last trading date for voting eligibility, according to Sharenet.

Aspen's fiscal 2026 results show the cash effect of that strategy. The company generated free cash flow before dividends of ZAR 3.8 billion, while the APAC divestment delivered gross proceeds of ZAR 28.0 billion and a profit on sale of ZAR 2.4 billion, according to Aspen Pharmacare.

Chronology shows a reshaped portfolio

On July 20, 2026, Aspen received Health Canada approval for Aspen-Semaglutide, a generic injectable for adults with type 2 diabetes, although commercialization depends on active pharmaceutical ingredient supply, as reported by SA Shares. On May 29, 2026, the APAC transaction closed with aggregate net proceeds of ZAR 28.0 billion, according to Aspen's investor-relations materials. On September 2, 2026, Aspen published fiscal 2026 results showing revenue of ZAR 34.9 billion, down from ZAR 35.3 billion, and operating profit of ZAR 763.0 million after a loss of ZAR 790.0 million in the prior year, as reported by SA Shares.

Dates and fiscal 2027 targets

Aspen's integrated report is scheduled for release at the end of October 2026, followed by the annual general meeting on December 3, 2026, according to the October 2 notice. The company is targeting normalized EBITDA of at least ZAR 9.0 billion in fiscal 2027 and raised sterile finished-dose-form EBITDA guidance from ZAR 1.7 billion to ZAR 2.2 billion, figures published in the company's investor-relations materials.

Cash generation remains central

The financial picture combines lower reported revenue with stronger cash conversion and a sharper manufacturing emphasis. Aspen's investor-relations page states that normalized EBITDA increased 10 percent to ZAR 7.7 billion in fiscal 2026, while free cash flow before dividends reached ZAR 3.8 billion.

The further course of trading is shown by the continuously updated real-time quote of Aspen stock.